Implications of EU Approval for J&J's Self-Administered Daratumumab

The Committee for Medicinal Products for Human Use of the European Medicines Agency to approve Johnson & Johnson’s type II variation for daratumumab.1 This regulatory update enables the subcutaneous formulation of this CD38-directed antibody to be administered by patients or their caregivers starting from the fifth dose. The adoption of daratumumab represents a major achievement in the application of delivery technologies, specifically the co-formulation of daratumumab with recombinant human hyaluronidase PH20, which utilizes Halozyme’s ENHANZE drug delivery technology. As the first anti-cancer injectable approved for self-administration in Europe, this development highlights a successful transition from clinic-based infusion to a more flexible subcutaneous model that maintains established safety and efficacy.

The technical success of this therapy is rooted in its ability to target CD38, a surface protein prevalent on multiple myeloma cells.1 By binding to this protein, the therapy inhibits tumor growth and induces cell death, a mechanism that has now been applied across ten distinct therapeutic indications, including light chain amyloidosis and various stages of multiple myeloma.

Ester in ‘t Groen, EMEA therapeutic area head Hematology, Johnson & Johnson, noted in a press release,1 “Daratumumab has played a transformative role in the treatment of multiple myeloma and has become a foundational therapy across the disease continuum since its first approval nearly a decade ago. Today we are proud to continue innovating with daratumumab, and this label update marks the first European approval of an anti-cancer injectable for self-administration.”

What Are the Clinical and Systemic Implications?

The shift toward self-administration addresses significant logistical bottlenecks in healthcare systems.1 By decentralizing the administration process, the pharmaceutical industry can help alleviate the pressure on hospital infrastructure while accommodating the evolving needs of the patient population.

This pivot toward patient-centric delivery is supported by clinical data from ten Phase III trials demonstrating significant improvements in survival outcomes for both newly diagnosed and relapsed patients.1 The move to home-based care is a direct response to the practical challenges faced by those undergoing long-term treatment.

Yusri Elsayed, MD, MHSc, PhD, global therapeutic area head of Oncology, Johnson & Johnson, explained in the press release,1 “For more than 20 years, Johnson & Johnson has been dedicated to advancing care for people living with multiple myeloma. Despite advances in treatment, patients continue to face significant challenges, and we remain focused on supporting the community through ongoing research, innovation and collaboration with healthcare professionals. Inspired by early real-world experiences, today’s milestone reflects our dedication to not only push the boundaries of science, but also to help ensure patients have access to treatment options that meet their evolving needs.”

From a development perspective, the partnership between Janssen Biotech and Genmab A/S to commercialize this therapy has resulted in its use by over 748,000 patients globally, underscoring the scale required for foundational oncology treatments.1 The ability to offer administration flexibility is a critical differentiator in a crowded therapeutic market.

Thomas Lund, MD, PhD, head of Hematological Section, Vejle Hospital, said in the press release,1 “For many patients living with multiple myeloma, treatment can involve frequent hospital visits and the challenge of fitting care around everyday life. The possibility for self-administration of daratumumab subcutaneous represents meaningful progress for those who would prefer the opportunity for greater flexibility in how or where they receive their care. For the medical community, it reduces pressure on healthcare systems and provides healthcare professionals with more choice in how they tailor treatment to individual needs and preferences, while maintaining the well-established safety profile and efficacy of daratumumab.”

How Is Targeted Drug Delivery Evolving Beyond Systemic Administration?

The industry’s focus on localized, patient-centric delivery is further exemplified by an investigational intravesical drug-releasing system for bladder cancer.2 This system, Erda-iDRS, provides prolonged release of erdafitinib directly into the bladder, reducing systemic exposure. Phase I results showed an 89% complete response rate in cases with FGFR alterations.

Antoni Vilaseca Cabo MD, adjunct physician of Urology Service, Hospital Clínic de Barcelona, noted in a press release,2 “In this study, treatment with Erda-iDRS led most patients with FGFR-altered disease to achieve a complete response by the end of the second treatment cycle, and many of those responses were sustained over time. Achieving and maintaining a complete response is particularly meaningful in this setting, where recurrence is common and requires repeated surgical intervention”. This Johnson & Johnson initiative marks a significant shift toward precision-based, biology-driven care.

References

1. Johnson & Johnson. Johnson & Johnson’s DARZALEX (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers. Beerse (Belgium): Johnson & Johnson; 2026 Mar 27. Press release.
2. Johnson & Johnson. Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non–muscle-invasive bladder cancer. Raritan (NJ): Johnson & Johnson; 2026 Mar 13. Press release. https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer